Alkem Labs eyes to raise Rs 1,000-1,500 via IPO: Report
19/01/2015 12:02
Mumbai-headquartered pharma firm Alkem Laboratories is planning to garner Rs 1,000-1,500 crore through public offering of its shares, two banks close to development told Mint. According to Mint report, the drug maker has not taken a final call on the initial public offering (IPO), as the promoters have not yet decided the exact size of stake sale. Alkem, a leading generic and specialty drug manufacturer, is India’s seventh largest pharmaceutical company with sales revenues exceeding USD 500 million, with a CAGR of 16 per cent over the last 5 years. Alkem is a pioneer in the acute and chronic therapeutic segments with manufacturing facilities across 7 locations in India, approved by global regulatory authorities including the US FDA, UK MHRA, MCC South Africa, evidences Alkem’s capabilities in offering quality generic and branded products in over 48 countries across the globe.
19/01/2015 12:02
Mumbai-headquartered pharma firm Alkem Laboratories is planning to garner Rs 1,000-1,500 crore through public offering of its shares, two banks close to development told Mint. According to Mint report, the drug maker has not taken a final call on the initial public offering (IPO), as the promoters have not yet decided the exact size of stake sale. Alkem, a leading generic and specialty drug manufacturer, is India’s seventh largest pharmaceutical company with sales revenues exceeding USD 500 million, with a CAGR of 16 per cent over the last 5 years. Alkem is a pioneer in the acute and chronic therapeutic segments with manufacturing facilities across 7 locations in India, approved by global regulatory authorities including the US FDA, UK MHRA, MCC South Africa, evidences Alkem’s capabilities in offering quality generic and branded products in over 48 countries across the globe.
